BIOPHYTIS (EPA:ALBPS) - Biophytis to attend the European Large & MidCap Event in Paris

Transparency directive : regulatory news

14/10/2019 08:00

Press Release

Biophytis to attend the European Large & MidCap Event in Paris

Paris (France), Cambridge (Massachusetts, United States), October 14, 2019,
08:00 CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company focused on the development of drug candidates for the
treatment of age-related diseases, with a primary focus on neuromuscular
diseases, today announces that Management will participate in the CF&B European
Large & MidCap Event which will take place from the 14th to 15th October 2019
in Paris, France.

****

About Biophytis
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases. Biophytis' lead drug candidate,
Sarconeos (BIO101), is an orally administered small molecule, which is
currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the US and
Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for
the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos
(BIO101) to be ready to enter the clinic for DMD in 2020, subject to regulatory
approval. Biophytis is headquartered in Paris, France, and has offices in
Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext
Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please
visit www.biophytis.com.

Disclaimer
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf-france.org) or on Biophytis' website (www.biophytis.com).

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.

Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
dan.schneiderman@biophytis.com
Tel: +1 (857) 220-9720

Europe Media Contact
Citigate Dewe Rogerson
Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible

biophytis@citigatedewerogerson.com
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis

BIOPHYTIS's latest news

18/04/2024 07:02

BIOPHYTIS (EPA:ALBPS) - Biophytis to attend the European Large & MidCap Event in Paris

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories